Supernus Pharmaceuticals announced strong financial results for the second quarter of 2024, marked by a 24% increase in total revenues to $168.3 million compared to the same period in 2023. Key growth drivers were Qelbree and GOCOVRI, with Qelbree net sales increasing by 92% and GOCOVRI by 10%. The company also reported an operating income of $22.6 million and adjusted operating earnings of $45.5 million. Supernus raised its full-year 2024 guidance for total revenues and operating earnings.
Net sales of Qelbree increased by 92% to $59.4 million compared to Q2 2023.
Net sales of GOCOVRI increased by 10% to $31.7 million compared to Q2 2023.
Total revenues increased by 24% to $168.3 million compared to Q2 2023.
Adjusted operating earnings increased to $45.5 million, compared to $10.0 million in the same period in 2023.
Supernus Pharmaceuticals is increasing its full year 2024 financial guidance for total revenues, GAAP operating earnings (loss) and non-GAAP operating earnings, and maintaining guidance for combined R&D and SG&A expenses.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance